Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFM 2014-02: Bortezomib + high-dose melphalan vs high-dose melphalan before autologous transplant in multiple myeloma
2014-000634-34Phase 3Terminated
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jul 2014
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Complete response rate at day 60 post-transplant. Started Jul 2014; status: terminated.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-000634-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000634-34.